Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Graham Dark.

Newcastle AuthorsTitleYearFull text
Dr Graham Dark
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial2022
Dr Graham Dark
Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial2021
Dr Graham Dark
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial2020
Dr Graham Dark
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor2019
Dr Graham Dark
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial2019
Dr Graham Dark
Impact of a 2-Week Oncology Placement on Medical Students’ Perception of Cancer2018
Dr Graham Dark
Professor Roderick Skinner
An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients2016
Dr Graham Dark
Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma - Results of an International Expanded Access Program2008
Dr Graham Dark
Rebecca Perrett
Deconstructing the construction of a learning module on practice development2007
Dr Graham Dark
Developing a web-based multidisciplinary cancer education forum2007
Dr Graham Dark
Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours2007
Dr Graham Dark
Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP)2007
Dr Graham Dark
Phase II study of vinflunine in malignant pleural mesothelioma2007
Dr Graham Dark
Rebecca Perrett
Practice development - Part 1: Developing a practice initiative in oncology and palliative care2007
Dr Graham Dark
Rebecca Perrett
Practice development - Part 2: evaluating a practice initiative2007
Dr Graham Dark
Rebecca Perrett
Using e-learning as a tool for multidisciplinary education2007
Dr Graham Dark
Helen Taylor
David Talbot
[Meeting Abstract] Vinflunine (VFL) in first line treatment of malignant pleural mesothelioma (MPM): Final results of a European phase II study2006
Dr Graham Dark
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)2006
Dr Graham Dark
Differentiation and definition of vascular-targeted therapies2005
David Talbot
Dr Graham Dark
Helen Taylor
Interim results of the phase II study of vinflunine (VFL) in malignant pleural mesotheliorna (MPM)2005
Dr Graham Dark
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial2005
Dr Graham Dark
Angela Price
Pernetrexed (P) plus carboplatin (Cb) as 1st treatment for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC): Results of both a multi-center European and an MD Anderson Cancer Center (MDACC) phase II trials2005
Dr Graham Dark
Proven bioequivalence of blood exposure between vinorelbine 80 mg/m(2) oral and 30 mg/m(2) IV doses in cancer patients.2005
Dr Graham Dark
Randomized phase II parallel evaluation of OSI-211 (liposomal lurtotecan) and topotecan in women with relapsed epithelial ovarian cancer (EOC)2005
Dr Graham Dark
Professor Alan Calvert
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the national cancer institute of Canada clinical trials group2005
David Talbot
Dr Jane Margetts
Dr Graham Dark
Helen Taylor
Vinflunine (VFL) in first line treatment of malignant pleural mesothelioma (MPM): Final results of a phase II study2005
Dr Graham Dark
Recent advances in mesothelioma2003